Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism

    Research output: Contribution to journalArticlepeer-review

    36 Scopus citations

    Abstract

    Background and purpose White matter hyperintensities (WMHs) in the cholinergic pathways are associated with cognitive performance in Alzheimer's disease (AD) and Parkinson disease dementia (PDD). This study aimed to evaluate the relationship between loss of white matter cholinergic pathways and cognitive function in patients with AD, diffuse Lewy body disease (DLB), and PDD. Methods The subjects included 20 patients with AD, 17 with DLB, 21 with PDD, and 20 healthy controls. The extent of WMHs within cholinergic pathways was assessed using the Cholinergic Pathways Hyperintensities Scale (CHIPS) and was compared among the different diseases. Results The mean CHIPS scores were similar among the three dementia groups (AD vs. DLB vs. PDD = 34.6 ± 17.9 vs. 32.4 ± 14.1 vs. 31.8 ± 14.5, p = 0.781 by ANCOVA) and higher than those of controls (11.5 ± 7.6, p = 0.001 by ANCOVA). Conclusions Losses of cholinergic pathways were similar among AD, DLB, and PDD groups, and more severe cognitive dysfunction was associated with elevated WMHs. These findings suggest that interruption of acetylcholine pathways may be related to cognitive dysfunction in these three diseases, even though they have different pathological mechanisms.

    Original languageEnglish
    Pages (from-to)44-48
    Number of pages5
    JournalJournal of the Neurological Sciences
    Volume353
    Issue number1-2
    DOIs
    StatePublished - 15 Jun 2015

    Bibliographical note

    Publisher Copyright:
    © 2015 Elsevier B.V.

    Keywords

    • Alzheimer's disease (AD)
    • Cholinergic Pathways Hyperintensities Scale (CHIPS)
    • Cognition
    • Diffuse Lewy body disease (DLB)
    • Magnetic resonance imaging
    • Parkinson disease dementia (PDD)

    Fingerprint

    Dive into the research topics of 'Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism'. Together they form a unique fingerprint.

    Cite this